Skin of Color pp 139-160 | Cite as

Disorders of Hyperpigmentation

  • So Yeon Paek
  • Amit G. Pandya


Acquired disorders of hyperpigmentation affect individuals of all skin types. However, pigmentary lesions may be more visible in skin of color and are often resistant to treatment. Dyschromias, in addition to acne, eczema, alopecia, and seborrheic dermatitis, are among the most common diagnoses in black patients seen by dermatologists. Etiology, diagnosis, treatment, and recommendations for melasma, postinflammatory hyperpigmentation, nevus of Ota/Ito, and periorbital hypermelanosis are reviewed.


Glycolic Acid Azelaic Acid Kojic Acid Seborrheic Dermatitis Fluocinolone Acetonide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Halder RM. Ethnic skin disorders overview. J Am Acad Dermatol. 2003;48 suppl 6:143–8.CrossRefGoogle Scholar
  2. 2.
    Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a ­comparative practice survey. Cutis. 2007;80:387–94.PubMedGoogle Scholar
  3. 3.
    Sivayathorn A. Melasma in orientals. Clin Drug Invest. 1995;10 suppl 2:34–40.Google Scholar
  4. 4.
    Hann SK, Im S, Chung WS, et al. Pigmentary disorders in the South East. Dermatol Clin. 2007;25:431–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Moin A, et al. Prevalence and awareness of melasma during pregnancy. Int J Dermatol. 2006;45:285.PubMedCrossRefGoogle Scholar
  6. 6.
    Werlinger KD, Jabery Z, Fallah N. Prevalence of self-diagnosed melasma among premenopausal Latino women in Dallas and Fort Worth, Tex. Arch Dermatol. 2007;143:424–5.PubMedGoogle Scholar
  7. 7.
    Goh CL, Dlova CN. A retrospective study on the clinical presentation and treatment outcome of melasma in a tertiary dermatological referral centre in Singapore. Singap Med J. 1999;40: 455–8.Google Scholar
  8. 8.
    Vasquez M, Maldonado H, Benmaman C, et al. Melasma in men: a clinical and histologic study. Int J Dermatol. 1988;27:25.CrossRefGoogle Scholar
  9. 9.
    Resnik S. Melasma induced by oral contraceptive drugs. JAMA. 1967;199:95.CrossRefGoogle Scholar
  10. 10.
    Lieberman R, Moy L. Estrogen receptor expression in melasma: results from facial skin of affected patients. J Drugs Dermatol. 2008;7(5):463–5.PubMedGoogle Scholar
  11. 11.
    Jee SH, Lee SY, Chiu HC, et al. Effects of estrogen and estrogen receptor in normal human melanocytes. Biochem Biophys Res Commun. 1994;199:1407–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Im S, Kim J, On WY, et al. Increased expression of α-melanocyte-stimulating hormone in the lesional skin of melasma. Br J Dermatol. 2007;146:165–7.Google Scholar
  13. 13.
    Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000;18:91–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Rigopoulos D, Gregoriou S, Katsambas A. Hyperpigmentation and melasma. J Cosmet Dermatol. 2007;6:195–202.PubMedCrossRefGoogle Scholar
  15. 15.
    Sanchez NP, Pathak MA, Sato S, et al. Melasma: a clinical, light microscopic, ultrastructural and immunofluorescence study. J Am Acad Dermatol. 1981;4(6):698–709.PubMedCrossRefGoogle Scholar
  16. 16.
    Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol. 2005;27:96–101.PubMedCrossRefGoogle Scholar
  17. 17.
    Balkrishnan R, McMichael AJ, Camacho FT, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149:572.PubMedCrossRefGoogle Scholar
  18. 18.
    Dominguez AR, Balkrishnan R, Ellzey AR, et al. Melasma in Latina patients: cross-cultural adaptation and validation of a quality-of-life questionnaire in Spanish language. J Am Acad Dermatol. 2006;55:59–66.PubMedCrossRefGoogle Scholar
  19. 19.
    Cestari TF, Hexsel D, Viegas ML, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol. 2007;156:13–20.CrossRefGoogle Scholar
  20. 20.
    Pathak MA, Riley FC, Fitzpatrick TB, et al. Melanogenesis in human skin following exposure to long-wave ultraviolet and visible light. J Invest Dermatol. 1962;39:435.PubMedGoogle Scholar
  21. 21.
    Mahmoud BH, Hexsel CL, Hamzavi IH, et al. Effects of visible light on the skin. Photochem Photobiol. 2008;84:450–62.PubMedCrossRefGoogle Scholar
  22. 22.
    Mahmoud BH, et al. Photobiologic effects of long wavelength UVA and visible light on melanocompetent skin. J Invest Dermatol. 2009;129 suppl 1:125.Google Scholar
  23. 23.
    Lakhdar H, Zouhair K, Khadir K, et al. Evaluation of the effectiveness of a broad-spectrum sunscreen in the prevention of chloasma in pregnant women. J Eur Acad Dermatol Venereol. 2007;21:738–42.PubMedCrossRefGoogle Scholar
  24. 24.
    Benchikhi H, Razoki H, Lakhdar H. Sunscreens: use in pregnant women at Casablanca. Ann Dermatol Venereol. 2002;129:387–90.PubMedGoogle Scholar
  25. 25.
    Vazquez M, Sanchez JL. The efficacy of a broad-spectrum sunscreen in the treatment of melasma. Cutis. 1983;32:92.PubMedGoogle Scholar
  26. 26.
    Ennes SBP, et al. A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of hydroquinone as a depigmenting agent in melasma. J Dermatol Treat. 2000;11:173–9.CrossRefGoogle Scholar
  27. 27.
    Charlin R, Barcaui CB, Kac BK, et al. Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy. Int J Dermatol. 2008;47:19–23.PubMedCrossRefGoogle Scholar
  28. 28.
    Nordlund JJ, Grimes P, Ortonne JP, et al. The safety of hydroquinone. J Eur Acad Dermatol Venereol. 2006;20:781–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20:308–13.PubMedCrossRefGoogle Scholar
  30. 30.
    Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975;111:40–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Taylor S, Torok H, Jones T, et al. Efficacy and safety of a new triple combination agent for the treatment of facial melasma. Cutis. 2003;72:67–72.PubMedGoogle Scholar
  32. 32.
    Torok H, Jones T, Rich P, et al. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis. 2005;75:57–62.PubMedGoogle Scholar
  33. 33.
    Grimes P, Kelly AP, Torok H, et al. Community-based trial of a triple-combination agent for the treatment of facial melasma. Cutis. 2006;77:177–84.PubMedGoogle Scholar
  34. 34.
    Chan R, Park KC, Lee MH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008;159:697–703.PubMedGoogle Scholar
  35. 35.
    Del Rosso JQ. The use of topical azelaic acid for common skin disorders other than inflammatory rosacea. Cutis. 2006;77((2 suppl)):22–4.PubMedGoogle Scholar
  36. 36.
    Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol (Stockh). 1989;143 ((suppl)):58–61.Google Scholar
  37. 37.
    Balina LM, Graupe K, et al. The treatment of melasma: 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991;30:893.PubMedCrossRefGoogle Scholar
  38. 38.
    Graupe K, Verallo-Rowell VM, Verallo V, et al. Combined use of 20% azelaic acid cream and 0.05% tretinoin in topical treatment of melasma. J Dermatol Treat. 1996;7:235–7.CrossRefGoogle Scholar
  39. 39.
    Garcia A, Fulton JE. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg. 1996;22:443.PubMedCrossRefGoogle Scholar
  40. 40.
    Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg. 1999;25:282–4.PubMedCrossRefGoogle Scholar
  41. 41.
    Gupta RR, Mahajan BB, Garg G, et al. Chemical peeling – evaluation of glycolic acid in ­varying concentrations and time intervals. Cosmetol. 2001;67:28–9.Google Scholar
  42. 42.
    Sarkar R, Kaur C, Ghalla M, et al. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg. 2002;28:828–32.PubMedCrossRefGoogle Scholar
  43. 43.
    Erbil H, Sezer E, Tastan B, et al. Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma. J Dermatol. 2007;34:25–30.PubMedCrossRefGoogle Scholar
  44. 44.
    Hurley ME, Guevara IL, Gonzales RM, et al. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol. 2002;138:1578.PubMedCrossRefGoogle Scholar
  45. 45.
    Garg VK, Sarkar R, Agarwal R, et al. Comparative evaluation of beneficiary effects of priming agents (2% hydroquinone and 0.025% retinoic acid) in the treatment of melasma with glycolic acid peels. Dermatol Surg. 2008;34:1032–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Grimes P. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg. 1999;25:18.PubMedCrossRefGoogle Scholar
  47. 47.
    Lawrence N, Cox SE, Brody HJ. Treatment of melasma with Jessner’s solution versus glycolic acid: a comparison of clinical efficacy and evaluation of the predictive ability of Wood’s light examination. J Am Acad Dermatol. 1997;36:589–93.PubMedCrossRefGoogle Scholar
  48. 48.
    Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid chemical peels as a new therapeutic modality in melasma in comparison to Jessner’s solution chemical peels. Dermatol Surg. 2006;32:1429–36.PubMedCrossRefGoogle Scholar
  49. 49.
    Kunachak S, Leelaudomlipi P, Wongwaisayawan S. Dermabrasion: a curative treatment for melasma. Aesthetic Plast Surg. 2001;25:114–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Bhalla M, Thami G. Microdermabrasion: reappraisal and brief review of literature. Dermatol Surg. 2006;32:809–14.PubMedCrossRefGoogle Scholar
  51. 51.
    Karimipour DJ, Karimipour G, Orringer JS. Microdermabrasion: an evidence-based review. Plast Reconstr Surg. 2010;125:372.PubMedCrossRefGoogle Scholar
  52. 52.
    Tse Y, Levine VJ, McClain SA, et al. The removal of cutaneous pigmented lesions with the Q-switched ruby laser and the Q-switched neodymium:yttrium-aluminum-garnet laser: a comparative study. J Dermatol Surg Oncol. 1994;20:795.PubMedGoogle Scholar
  53. 53.
    Polnikorn N. Treatment of refractory dermal melasma with the MedLite C6 Q-switched Nd:YAG laser: two case reports. J Cosmet Laser Ther. 2008;10:167–73.PubMedCrossRefGoogle Scholar
  54. 54.
    Manaloto RMP, Alster T. Erbium:YAG laser resurfacing for refractory melasma. Dermatol Surg. 1999;25:121.PubMedCrossRefGoogle Scholar
  55. 55.
    Ko NY, Ahn HH, Kim SN, et al. Analysis of erythema after Er:YAG laser skin resurfacing. Dermatol Surg. 2007;33:1322–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Rokhsar CK, Fitzpatrick RE. The treatment of melasma with fractional photothermolysis: a pilot study. Dermatol Surg. 2005;31:1645–50.PubMedCrossRefGoogle Scholar
  57. 57.
    Graber EM, Tanzi EL, Alster TS. Side effects and complications of fractional laser photothermolysis: experience with 961 treatments. Dermatol Surg. 2008;34:301–5.PubMedCrossRefGoogle Scholar
  58. 58.
    Goldberg DJ, Berlin AL, Phelps R. Histologic and ultrastructural analysis of melasma after fractional resurfacing. Lasers Surg Med. 2008;40:134–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Wang CC, Hui CY, Sue YM, et al. Intense pulsed light for the treatment of refractory melasma in Asian patients. Dermatol Surg. 2004;30:1196–200.PubMedCrossRefGoogle Scholar
  60. 60.
    Li YH, Chen JZ, Wei HC, et al. Efficacy and safety of intense pulsed light in treatment of melasma in Chinese patients. Dermatol Surg. 2008;34:693–701.PubMedCrossRefGoogle Scholar
  61. 61.
    Sriwiriyanont P, Ohuchi A, Hachiya A, et al. Interaction between stem cell factor and endothelin-1: effects on melanogenesis in human skin xenografts. Lab Invest. 2006;86:1115–25.PubMedGoogle Scholar
  62. 62.
    Ruiz-Maldonado R, Orozco-Covarrubias ML. Postinflammatory hypopigmentation and hyperpigmentation. Semin Cutan Med Surg. 1997;16:36–43.PubMedCrossRefGoogle Scholar
  63. 63.
    Nordlund JJ. Postinflammatory hyperpigmentation. Dermatol Clin. 1988;6:185.PubMedGoogle Scholar
  64. 64.
    Kim NY, Pandya AG. Pigmentary diseases. Office Dermatol. 1998;82:1185–207.Google Scholar
  65. 65.
    Bulengo-Ransby S, Griffiths CD, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328:1438–43.PubMedCrossRefGoogle Scholar
  66. 66.
    Grimes P. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis. 2004;74:362–8.PubMedGoogle Scholar
  67. 67.
    Baumann L, Grimes P, Pandya AG, Rendon M, Taylor S. Poster #1887, World congress of dermatology. Buenos Aires; 30 Sept–5 Oct 2007.Google Scholar
  68. 68.
    Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis. 2006;77:45–50.PubMedGoogle Scholar
  69. 69.
    Burns RL, Prevost-Blank PL, Lawry MA, et al. Glycolic acid peels for postinflammatory hyperpigmentation in black patients. Dermatol Surg. 1997;23:171–5.PubMedCrossRefGoogle Scholar
  70. 70.
    Joshi SS, Boone SL, Alam M, et al. Effectiveness, safety, and effect on quality of life of topical salicylic acid peels for treatment of postinflammatory hyperpigmentation in dark skin. Dermatol Surg. 2009;35:638–44.PubMedCrossRefGoogle Scholar
  71. 71.
    Ahn HH, Kim IH. Whitening effect of salicylic acid peels in Asian patients. Dermatol Surg. 2006;32:372–5.PubMedCrossRefGoogle Scholar
  72. 72.
    Garg VK, Sinha S, Sarkar R. Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatol Surg. 2009;35:59–65.PubMedCrossRefGoogle Scholar
  73. 73.
    Qian Y, Zakov ZN, Schoenfield L, et al. Iris melanoma arising in iris nevus in oculo (dermal) melanocytosis. Surv Ophthalmol. 2008;53:411–5.PubMedCrossRefGoogle Scholar
  74. 74.
    Sekar S, Kuruvila M, Pai HS. Nevus of Ota: a series of 15 cases. Indian J Dermatol Venereol Leprol. 2008;74:125–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Torres JE, Sanchez JL. Melasma and other disorders of hyperpigmentation. In: Arndt KA, LeBoit PE, Robinson JK, Wintroub BU, editors. Cutaneous medicine and surgery, vol. 2. Philadelphia: W.B. Saunders; 1996. p. 1239–40.Google Scholar
  76. 76.
    Hidano A, Kajima H, Ikeda S, et al. Natural history of nevus of Ota. Arch Dermatol. 1967;95:187–95.PubMedCrossRefGoogle Scholar
  77. 77.
    Agero AL, Lahmar JJ, Holzborn RM, et al. Naevus of Ota presenting in two generations: a mother and daughter. J Eur Acad Dermatol Venereol. 2009;23:102–4.PubMedCrossRefGoogle Scholar
  78. 78.
    Sinha S, Cohen PJ, Schwartz RA. Nevus of ota in children. Cutis. 2008;82:25–9.PubMedGoogle Scholar
  79. 79.
    Chan HH, Lam LK, Wong DS, et al. Nevus of ota: a new classification based on the response to laser treatment. Lasers Surg Med. 2001;28:267–72.PubMedCrossRefGoogle Scholar
  80. 80.
    Hirayama T, Suzuki T. A new classification of Ota’s nevus based on histopathological features. Dermatologica. 1991;183:169–72.PubMedCrossRefGoogle Scholar
  81. 81.
    Mosher DB, Fitzpatrick TB, Ortonne J-P, Hori Y. Hypomelanoses and hypermelanoses. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, editors. Fitzpatrick’s dermatology in general medicine. 5th ed. New York: McGraw-Hill; 1999. p. 1004.Google Scholar
  82. 82.
    Watanabe S. Basics of laser application to dermatology. Arch Dermatol Res. 2008;300 suppl 1:S21–30.PubMedCrossRefGoogle Scholar
  83. 83.
    Kagami S, Asahina A, Watanabe R, et al. Treatment of 153 Japanese patients with Q-switched alexandrite laser. Lasers Med Sci. 2007;22:159–63.PubMedCrossRefGoogle Scholar
  84. 84.
    Wang HW, Liu UH, Zhang GK, et al. Analysis of 602 Chinese cases of nevus of Ota and the treatment results treated by Q-switched alexandrite laser. Dermatol Surg. 2007;33:455–60.PubMedCrossRefGoogle Scholar
  85. 85.
    Kang W, Lee E, Choi GS. Treatment of Ota’s nevus by Q-switched alexandrite laser: therapeutic outcome in relation to clinical and histopathological findings. Eur J Dermatol. 1999;9: 639–43.PubMedGoogle Scholar
  86. 86.
    Chan HH, Leung RS, Ying SY, et al. Recurrence of nevus of Ota after successful treatment with Q-switched lasers. Arch Dermatol. 2000;136:1175–6.PubMedCrossRefGoogle Scholar
  87. 87.
    Trindade F, Cabecadas J, Rosa J. Surgical management of the eyelid and bulbar conjunctiva in a patient with nevus of Ota. J Eur Acad Dermatol Venereol. 2008;22:618–20.PubMedCrossRefGoogle Scholar
  88. 88.
    Goodman RM, Belcher RW. Periorbital hyperpigmentation. Arch Dermatol. 1969;100: 169–74.PubMedCrossRefGoogle Scholar
  89. 89.
    Malakar S, Lahiri K, Banerjee U, et al. Periorbital melanosis is an extension of pigmentary demarcation line-F on face. Indian J Dermatol Venereol Leprol. 2007;73:323–5.PubMedCrossRefGoogle Scholar
  90. 90.
    Selmanowitz VJ, Krivo JM. Pigmentary demarcation lines: comparison of Negroes with Japanese. Br J Dermatol. 1975;93:371–7.PubMedCrossRefGoogle Scholar
  91. 91.
    Somani VK, Razvi F, Sita VN. Pigmentary demarcation lines over the face. Indian J Dermatol Venereol Leprol. 2005;70:336–41.Google Scholar
  92. 92.
    West TB, Alster TS. Improvement of infraorbital hyperpigmentation following carbon dioxide laser resurfacing. Dermatol Surg. 1998;24:615–6.PubMedCrossRefGoogle Scholar
  93. 93.
    Momosawa A, Kurita M, Miyamoto S, et al. Combined therapy using Q-switched ruby laser and bleaching treatment with tretinoin and hydroquinone for periorbital skin hyperpigmentation in Asians. Plast Reconstr Surg. 2008;121:282–8.PubMedCrossRefGoogle Scholar
  94. 94.
    Lowe NJ, Wieder JM, Shorr N, et al. Infraorbital pigmented skin: preliminary observations of laser therapy. Dermatol Surg. 1995;21:767.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.DetroitUSA
  2. 2.Henry Ford HospitalDetroitUSA
  3. 3.Department of DermatologyUniversity of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations